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Abstract
Background: Fatigue is prevalent in breast cancer survivors and has profound effects on daily life. The interference
of fatigue with endocrine therapy may be difficult to separate. This study investigates the prevalence and severity
of fatigue and identifies the demographic, clinical, and lifestyle factors associated with cancer-related fatigue (CRF)
in breast cancer patients undergoing endocrine therapy in an urban area.
Methods: Women with stage I-IIIA breast cancer were recruited and asked to participate (n = 371) in the study.
The 315 women who responded to the questionnaire (84.9%), 54 (17.1%) had completed endocrine therapy and
261 (82.9%) were still undergoing endocrine therapy. The patients had been diagnosed at an average of 31
months prior to recruitment (range, 7 to 60 months); the average age was 48 (range, 33 to 72) years. The 11-point
scale and Visual Analog Scale (VAS) were employed to quantify the level of fatigue experienced by the patients.
Logistic regression analyses and a trend test method were performed to evaluate factors associated with CRF.
Results: Among the 315 patients, 189 (60%) had experienced or were experiencing CRF during endocrine therapy.
Logistic regression analysis was performed to identify factors associated with CRF, including BMI (body mass index),
clinical stage, menopausal status, duration of endocrine therapy, physical activity, and diet. Factors unrelated to CRF
were age, marital status, treatment, endocrine therapy drugs, alcohol intake, and smoking. The trend test method
revealed an association between physical activity and dietary level and the intensity of CRF.
Conclusions: The present findings suggest that fatigue is an important problem in the majority of breast cancer
patients during endocrine therapy. We found that BMI, clinical stage, menopausal status, duration of endocrine
therapy, physical activity, and diet are associated with fatigue. Future research should focus on the impact factors
of CRF and lifestyle in the management of breast cancer patients.
Background
Cancer survivors comprise a vulnerable population that
has distinct therapy needs. A large proportion of cancer
patients experience cancer treatment-related physical
and mental symptoms. Fatigue is the most frequently
reported symptom among cancer patients [1-6], with an
estimated 60-96% of cancer patients who are undergoing
treatment experiencing fatigue, including 60-93% of
radiotherapy and 80-96% chemotherapy patients [5-7].
Cancer-related fatigue (CRF) is a distressing, persistent,
and subjective sense of physical, emotional and/or cog-
nitive tiredness or exhaustion related to cancer or can-
cer treatment that is not proportional to recent activity
and interferes with normal functioning [8]. Compared
with the fatigue experienced by healthy individuals, CRF
is more severe, more distressing [9,10], and is less likely
to be relieved by rest [11]. Patterns of the occurrence of
fatigue may differ according to the type of treatment
[12] and the stage of cancer [13].
Breast cancer is notable for causing long-term treat-
ment effects that begin during the treatment period and
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prominent in women with breast cancer, including fati-
gue, hot flashes, sexual dysfunction, infertility, bone loss,
and cognitive dysfunction [15]. Studies indicate that the
prevalence of fatigue is high in patients with breast can-
cer; as many as 99% of these patients experience fatigue
during the course of treatment [16]. CRF could be
mediated by the endocrine sequelae of breast cancer
treatment, including the induction of amenorrhea, the
induction of premature menopause due to ovarian toxi-
city caused by chemotherapy, radiotherapy and the side
effects of adjuvant endocrine treatment [17]. It has been
proposed that hormone treatment has minimal effects
on fatigue and menopausal symptoms. However, adju-
vant chemotherapy leads to severe fatigue and meno-
pausal symptoms during and after treatment, and worse
symptoms are observed with chemotherapy-induced
treatment than with natural menopause [18]. The inter-
ference of fatigue with menopausal symptoms, however,
may be difficult to elucidate, especially in young breast
cancer patients who face premature and sudden meno-
pause and prolonged oestrogen deprivation.
Endocrine therapy was proposed as a treatment for
breast cancer, especially in patients who had undergone
premature menopause and in post-menopausal women
with hormone-responsive, oestrogen receptor-positive
tumors. Fatigue in breast cancer survivors may be more
distressing than fatigue in the general population,
because many women experience premature menopause
due to chemotherapy or oestrogen deprivation treatment
and thus experience menopause-related fatigue more
abruptly and earlier in life than do those with a more
natural menopausal transition [14,15]. Gélinas C et al.
also showed that persistent fatigue in younger breast
cancer patients following the completion of therapy was
related to menopausal symptoms [19].
Activity enhancement and psychosocial interventions
are two nonpharmacologic interventions with strong evi-
dence for the treatment of fatigue. Regular exercise leads
to a decrease in fatigue, depression, and anxiety both
during [20-22] and after [23-26] cancer treatment in
breast cancer patients. However, there is also some evi-
dence that dietary management and sleep therapy can
relieve fatigue symptoms [27].
Thus, it can be hypothesised that menopausal status
and therapies in patients with breast cancer may partici-
pate in the development of fatigue. In contrast to fatigue
during chemotherapy and radiotherapy, fatigue during
endocrine therapy in women with breast cancer has
been reported less frequently. We hypothesised that
some demographic and clinical factors, such as age, BMI
(body mass index), clinical stage, menopausal status, and
duration of endocrine therapy, are associated with CRF
in breast cancer during endocrine therapy. We also
hypothesised that some effective nonpharmacologic
interventions, such as physical activity and diet, could
improve CRF.
Methods
Participants
A cross-sectional study was performed to assess women
living with breast cancer who had completed or were
undergoing endocrine therapy in an urban area. These
patients were diagnosed with breast cancer and/or
received treatment for breast cancer at the Tumor
Hospital of Harbin Medical University, Harbin, China,
between June 2004 and September 2009. Patients had
b e e nd i a g n o s e da ta na v e r a g eo f3 1m o n t h sp r i o rt o
recruitment (range, 7 to 60 months); the average age
was 48 (range, 33 to 72) years. All cases were confirmed
by a pathological examination; oestrogen receptor (ER)
and progesterone receptor (PR) statuses were evaluated
by standard immunohistochemistry. All patients were
ER-positive and PR-positive or PR-negative. The eligibil-
ity criteria for study participation were as follows: a) at
least 18 years of age, b) no documented or observable
psychiatric or neurological disorders that would interfere
with participation, c) women diagnosed with stage I-IIIA
breast cancer, d) no history of another cancer other than
basal cell skin carcinoma, e) no other chronic or life-
threatening diseases in which fatigue is a prominent
symptom (e.g., multiple sclerosis, rheumatoid arthritis,
fibromyalgia, or chronic fatigue syndrome), f) previous
surgical treatment for breast cancer, g) completed or
undergoing endocrine therapy, h) endocrine therapy for
more than six months, and i) provision of written
informed consent.
Questionnaires Procedures
Recruitment strategies included interviews with women
who were identified from tumor registries and referrals
from clinical oncologists. Eligibility was determined
based on a chart review and consultation with the
attending physician. One of these women was randomly
selected and sent a letter of introduction. Three hun-
dred and seventy-one women were considered eligible
and asked to participate in the study, and 333 accepted.
Those women who provided informed consent were
instructed to complete a series of questionnaires that
assessed factors associated with CRF. In total, 315
women responded to the questionnaire (Additional file
1) (84.9%). Among the 315 patients, 54 patients (17.1%)
had completed endocrine therapy, 261 patients (82.9%)
were undergoing endocrine therapy, and the incidence
of premature menopause was 27.6%. The remaining
patients were excluded because a complete data set was
not available due to inaccurate filing and missing or
unavailable records. The address, phone number, and
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treating physician was contacted for permission to con-
tact the patient. For some patients, endocrine therapy
had been initiated five years prior, but other patients
were still undergoing endocrine therapy. However, our
hospital had a regular follow-up system and documenta-
tion from the first admission to death. These records
helped the two groups of patients recall their conditions,
thereby improving the accuracy of the questionnaire
contents and avoiding bias.
The survey, which was designed to be self-reported,
included items that provided the following information:
age, BMI, marital status, alcohol intake, smoking, meno-
pausal status, clinical stage, endocrine therapy status,
CRF degree, physical activity level, and dietary assess-
ment. The ethics committee of Tumor Hospital of Har-
bin Medical University approved the study.
Questionnaires
Cancer-related fatigue levels
The patients were screened for fatigue using the 11-
point scale [28] (0 = not fatigued, 10 = extremely fati-
gued) and the Visual Analog Scale (VAS) [29,30], which
assessed the level of fatigue among the respondents. The
fatigue scale for adults was based on a 0-10 point scale.
Using the scale, fatigue was divided into the following
categories: none (0 points), mild (1-3 points), moderate
(4-6 points), and severe (7-10 points). Clinical experi-
ence with the assessment of fatigue has shown that
some patients cannot define their fatigue based on a
numeric value. This small group of patients rated their
fatigue on the VAS. VAS is frequently used to assess
subjective feelings such as pain and fatigue [29]. The
answer line of 100 mm ranges from “not at all fatigued”
to “as fatigued as I could be.” VAS was divided into
three parts of equal, and fatigue was classified into cate-
gories as follows: none (0 mm), mild, moderate, or
severe. Consequently, all of the patients classified fatigue
as mild, moderate, or severe. The respondents indicated
whether their fatigue had changed during endocrine
therapy, and fatigue was assessed when the participant
was completing the questionnaire.
Physical activity levels
The intensity, duration, and frequency of physical activ-
ity were self-reported by the participants and converted
into metabolic equivalents (METs). Activity choices
included the following: walking or hiking outdoors, jog-
ging (> 10 minutes per mile), running (≤ 10 minutes per
mile), biking (including stationary bike), swimming laps,
tennis, callisthenics, aerobics, aerobic dance, rowing
machine, among others. Qigong and Tai Chi Chuan
were both considered types of aerobic exercise. Levels of
general physical activity and walking were assessed sepa-
rately and combined to achieve a measurement of total
METs. Total energy expenditure was determined by
analyzing the time (minutes) spent on physical activity
per week by METs; it was then divided into the follow-
ing categories: light physical activity (< 3 METs), moder-
ate activity (3-6 METs), and vigorous activity (> 6
METs). Walking was assigned a value of 2, 3, 4 or
6 METs based on the walking speed, which was charac-
terised as slow, average, fast, or very fast [31]. Total
METs were calculated by summing the METs deter-
mined for each category of activity and multiplying the
result by the duration in minutes. The MET-hours/week
(MHW) was then calculated by dividing the total METs
by 60 [32]. Physical activity was assessed and categorised
based on the MET task hours per week (MHW) as
follows: 3.3≤ MHW < 10, 10≤ MHW < 20, MHW ≥ 20.
Dietary assessments
Typical data for dietary intakes were obtained via the
participants’ self-reports. According to the Dietary
Guidelines For Chinese Residents (2007), the daily
intake of an average person should be as follows: A. cer-
eals, 250-400 g; B. vegetables and fruits, 300-500 g and
200-400 g, respectively; C. fish and shrimp, 50 g; poultry
and meat, 50-100 g; eggs, 25-50 g; D. milk and milk
products, 100 g; beans and bean products, 30-50 g;
E. fats and oil, less than 25 g. The levels of these nutri-
ents were calculated according to the intake of A to E;
each category represented 1 point. Scores were added
up to yield a final score that ranged from 0 (met none
of the recommendations) to 5 (met all of the recom-
mendations). The dietary assessment was categorised as
follows: 0, 1-2, 3-4, and 5.
Statistical analysis
All analyses were based on data obtained from the
aforementioned questionnaires, which were certified by
clinical oncologists and by the participants themselves.
Multiple logistic regression analyses were employed to
determine factors associated with CRF in breast cancer
patients undergoing endocrine treatment. The trend test
method was used to evaluate the association between
physical activity and dietary level and the intensity of
CRF. All statistical analyses were performed using SPSS
13.0 software.
Results
Among the three hundred and fifteen patients who
responded to the questionnaire, 189 (60%) experienced
or were experiencing CRF during endocrine therapy.
Table 1 illustrates the demographic data for the patients
that were included in the study. Among the 315
patients, those with mild, moderate, and severe fatigue
comprised 44.8%, 9.8% and 5.4% of the study popula-
tion, respectively. Within these 189 patients, 173 (91.5%)
had reduced CRF, whereas 16 (8.5%) had the same or
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formed to identify factors that were associated with
CRF. As shown in Table 2, the significant factors asso-
ciated with CRF included BMI, clinical stage of the
tumor, menopausal status, duration of endocrine ther-
apy, physical activity, and diet. Age, marital status, treat-
ment types, drugs used for endocrine therapy, alcohol
intake, and smoking did not affect CRF.
In the 173 patients who showed a reduced level of
fatigue, a correlation was detected between physical
activity and dietary level and the intensity of CRF, as
demonstrated in Table 3. Those patients with a reduced
level of CRF showed the following CRF intensity and
mean physical activity level: mild CRF/15.0 MHW; mod-
erate CRF/11.5 MHW; severe CRF/6.7 MHW. The aver-
age physical activity level of patients with reduced CRF
was 823 METs/week (or 13.7 MHW). The trend test
method showed that the intensity of CRF decreased
with an increase in physical activity (p < 0.05). Among
these patients who had reduced CRF, 43.9% and 24.9%
of the patients performed Qigong and Tai Chi, respec-
tively, and 11.2% performed both Qigong and Tai Chi.
A total of 83.7% of the patients with mild relievable
CRF and 59.6% of the patients with moderate relievable
CRF demonstrated an active or a highly active physical
activity level (10.0 ≤ MHW < 20.0 or MHW ≥ 20.0).
Among the patients who showed relieved CRF, approxi-
mately 45.7% achieved 5 points in the dietary assess-
ment. Another 27.5%, 11.8%, 8.7%, 5.2% and 1.2% of
patients demonstrated dietary levels of 4, 3, 2, 1 and 0,
respectively. Approximately 81.1% of the patients
Table 1 Information of Subjects(Total 315 patients)
Category Number and
percentage
N(%)
1. Age(year)
30–49 156(49.4)
50–64 102(32.4)
≥ 65 57(18.2)
2. Body mass index(kg/m
2)
a
≤ 25 kg/m
2 240(76.1)
> 25 kg/m
2 75(23.9)
3. Marital status
Married 293(93.0)
Single 22(7.0)
4. Menopausal status
Pre-menopause 113(36.0)
Post-menopause 202(64.0)
5. Clinical stage
Stage I 72(22.9)
Stage II 135(42.9)
Stage IIIA 108(34.3)
6. Treatment
Surgery + endocrine therapy 21(6.7)
Surgery + radiation + endocrine therapy 48(15.2)
Surgery + chemotherapy + endocrine
therapy
91(28.9)
Surgery + chemotherapy + radiation +
endocrine therapy
155(49.2)
7. Drugs for endocrine therapy
Pre-menopause
Tamoxifen 143(45.4)
Post-Menopause
Tamoxifen 38(12.1)
Aromatase inhibitors 134(42.5)
8. Duration of endocrine therapy
> 6 Months to 3 years 173(54.9)
> 3 years to 5 years 142(45.1)
9. Alcohol intake
yes 61(19.4)
no 254(80.6)
10. Smoking
yes 4(1.3)
no 311(98.7)
a. Body mass index (BMI): BMI > 25 kg/m
2 indicates overweight;
BMI > 30 kg/m
2 indicates obese.
Table 2 Logistic Regression Analysis to Identify Factors
Associated with CRF
95% CLs
Odds Ratio Lower Upper P
Body mass index 3.200 0.959 10.684 0.0586
Cinical stage 11.720 1.331 103.212 0.0266
Menopausal status 7.331 1.531 35.099 0.0127
Duration of endocrine therapy 5.491 1.043 28.901 0.0444
Physical activity 2.765 0.960 7.962 0.0595
Diet 0.242 0.097 0.605 0.0024
Table 3 The correlation between the intensity of CRF and
the level of physical activity and diet in patients with
relieved CRF
Intensity of Fatigue
Mild Moderate Severe P
N% N %N%
1. Physical Activity < 0.0001
MHW < 3.3 0 0 1 2.7 3 42.9
3.3≤ MHW < 10.0 21 16.3 14 37.8 2 28.6
10.0≤ MHW < 20.0 88 68.2 16 43.2 2 28.6
MHW ≥ 20.0 20 15.5 6 16.2 0 0
2. Diet 0.02
0 0 0 1 2.7 1 14.3
1~2 16 12.4 6 16.2 2 28.6
3~4 52 40.3 13 35.1 3 42.9
5 61 47.3 17 45.9 1 14.3
Statistically significant (p < 0.05)
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obtained 15-20% from proteins and fats, and 61.8% con-
sumed a satisfactory amount of fruits and vegetables.
The trend test method showed that the intensity of
CRF decreased with an increase in the dietary level
(p < 0.05).
Discussion
The impact of CRF on quality of life and the ability to
carry out activities of daily living have profound implica-
tions for patients, especially those who experience a
noticeable decline in their functional status while under-
going cancer treatment [1,33]. It has been reported that
the side effects of hormone cancer treatment or hor-
mone deprivation may unduly impair quality of life
[34,35]. In addition to hormone cancer treatment and
hormone deprivation, CRF has been associated with the
increased production of different cytokines, increased
tumor growth, impaired energy transformation processes
and many other cancer-related pathologies [16,36]. The
phenomenon of CRF is complex and multifactorial and
is currently not fully understood.
In the present study, 60% of the patients were experi-
encing or had experienced CRF during endocrine ther-
apy. These findings support the available evidence that
occurrence rates for fatigue are generally higher in other
cancer populations than in breast cancer patients [36].
Malinovsky et al. suggested that different levels of fati-
gue were associated with different groups of anti-hor-
mones [37]. However, the type of endocrine therapy
drug used was not associated with fatigue in our study.
This finding may suggest that CRF is not associated
with anti-oestrogens, which are used to treat breast can-
cer patients.
W ef o u n dt h a tB M Ic o r r e l a t e dw i t hC R Fa n dt h a t
23.9% of the patients were overweight. BMI tends to
increase in women who have undergone breast cancer
treatment [38], due to changes in hormone levels [39],
altered eating behaviours [40], and other psychological
factors [41]. Rock CL et al. suggested that obesity was a
side effect of endocrine therapy [42]. To achieve a bal-
ance between adequate nutrition and energy consump-
tion, professional interventions such as a combination of
diet changes and physical activity may be more effective
[43-45]. Goodwin et al. suggested that an evaluation of
diet and physical activity should be conducted within one
year after the diagnosis of early stage breast cancer [46].
In our study, the degree of CRF was further correlated
with the clinical stage, the menopausal status and dura-
tion of endocrine therapy. The pre-menopausal patients
showed a greater tendency toward CRF during the first
3 years of the endocrine therapy. The early detection of
fatigue will provide important information to guide the
clinical management of CRF, such as the timing [13]
and the types of treatment [12]. CRF should be screened
and evaluated according to clinical guidelines to provide
patients with an accurate consultation and appropriate
management.
Among the non-pharmacologic interventions, exercise
showed the strongest evidence for a positive effect in
the management of CRF [43,44,47,48]. Physical activity
has been beneficial in improving symptoms of fatigue in
breast cancer survivors [49-52]. In the present study,
61.3% of the patients who reduced CRF demonstrated
active physical activity levels. This result might be due
to the finding that most of the patients suffered from
mild CRF (74.6%); they could perform some higher than
moderate levels of exercise. Traditional Chinese sports
games such as Qigong and Tai Chi are typical aerobic
activities and are considered high-level physical activities
(> 6 METs), which is above the suggested physical activ-
ity level. Current recommendations for exercise among
cancer patients are walking at a moderate pace for up to
30 min/day (slowly building up to 30 min/day) three or
more times per week [15]. Moderate rather than vigor-
ous exercise is preferable for patients and results in
increased compliance [53]. Further investigation is
required to determine whether the present results are
applicable to breast cancer patients with CRF.
Regarding the effects of diet on CRF, we found that a
greater number of points for diet correlated with a
lower CRF intensity. Among the patients with relieved
CRF, 72.3% demonstrated a dietary level of 4 or 5. Thus,
we can speculate that most cancer patients in large and
medium-sized cities have a satisfactory diet with
balanced nutrition. Other studies have shown that mul-
tiprofessional patient management is critical for patient
recovery, including dietary counselling, nutrition inter-
vention, and medicine [1,54]. Physical activities can
improve appetite, relieve constipation [54], and maintain
sufficient nutritional stores, which will certainly benefit
the health of the patient [3,55].
Limitations
The results of this study reflect the retrospective nature
of the self-reported data, and they may demonstrate a
potential recall bias. However, during endocrine treat-
ment of breast cancer in women, this limitation of the
data also provides significant information. The data
show the prevalence and severity of fatigue, as well as
the demographic, clinical, and lifestyle factors associated
with CRF in breast cancer patients undergoing endo-
crine treatment in an urban area.
Conclusions
The present findings suggest that fatigue is an important
problem in the majority of breast cancer patients during
endocrine therapy. We found that BMI, clinical stage,
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cal activity, and diet are associated with fatigue. Future
research should focus on the impact factors of CRF and
lifestyle in the management of breast cancer patients.
Additional material
Additional file 1: Questionnaire (Breast Cancer). This questionnaire
was used to investigate factors associated with cancer-related fatigue
among breast cancer during endocrine treatment in an urban area.
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